Latest Updates

The shares were listed at Rs 523.95 per share

The patents from the US and New Zealand are valid until 2030 and 2031

IPM valued at Rs 89,244 crores

Discussions were held to understand key regulatory issues related to excipients

To sign an MoU between the US FDA and the Export Inspection Council of India

Discussions will be held on opportunities for growth, challenges and way forward

The company has received approval for generic sofosbuvir tablets in the strength of 400 mg from Drugs Controller General (India)

Makes Rs 26-crore payments towards TDS, PF

The patents are valid through 2029 and 2030

Also launches Pharma Jan Samadhan, online facility to redress consumer complaints on drug pricing and availablity